{"entity":{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","aka":[],"tldr":"A randomised phase 2 found that adding the GSK-3 inhibitor elraglusib to standard chemotherapy lengthened survival in metastatic pancreatic cancer; a phase 3 is needed to confirm it.","summary":"Part 3B of the Actuate 1801 study randomised patients with previously untreated metastatic pancreatic ductal adenocarcinoma to gemcitabine and nab-paclitaxel with or without elraglusib. The company reported improved overall survival and one-year survival with elraglusib. As a phase 2 result it is hypothesis-generating, and Actuate has said a confirmatory phase 3 is planned.","status":"positive","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03678883","url":"https://clinicaltrials.gov/study/NCT03678883"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["elraglusib","gemcitabine-nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03678883","phase":"2","setting":"Untreated metastatic pancreatic adenocarcinoma: gemcitabine and nab-paclitaxel with or without elraglusib","sponsor":"Actuate Therapeutics","result":"Overall survival longer with elraglusib in a randomised phase 2; confirmation pending.","yearReported":2025,"outcomes":[]},"route":"/trials/actuate-1801/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"elraglusib","kind":"drug","name":"Elraglusib","route":"/drugs/elraglusib/"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"}]}}